SI21369A - Geldanamicinski derivat in postopek zdravljenja raka z uporabo le-tega - Google Patents

Geldanamicinski derivat in postopek zdravljenja raka z uporabo le-tega Download PDF

Info

Publication number
SI21369A
SI21369A SI200220013A SI200220013A SI21369A SI 21369 A SI21369 A SI 21369A SI 200220013 A SI200220013 A SI 200220013A SI 200220013 A SI200220013 A SI 200220013A SI 21369 A SI21369 A SI 21369A
Authority
SI
Slovenia
Prior art keywords
compound
hydrogen
compounds
host
geldanamycin
Prior art date
Application number
SI200220013A
Other languages
English (en)
Slovenian (sl)
Inventor
Kenneth M. SNADER
Rao B. Vishnuvajjala
Melinda G. Hollingshead
Edward A. SAUSVILLE
Original Assignee
The United States Of America, Represented By The Secretary,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America, Represented By The Secretary, filed Critical The United States Of America, Represented By The Secretary,
Publication of SI21369A publication Critical patent/SI21369A/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI200220013A 2001-03-30 2002-03-28 Geldanamicinski derivat in postopek zdravljenja raka z uporabo le-tega SI21369A (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28007801P 2001-03-30 2001-03-30
PCT/US2002/010097 WO2002079167A1 (en) 2001-03-30 2002-03-28 Geldanamycin derivative and method of treating cancer using same

Publications (1)

Publication Number Publication Date
SI21369A true SI21369A (sl) 2004-06-30

Family

ID=23071560

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200220013A SI21369A (sl) 2001-03-30 2002-03-28 Geldanamicinski derivat in postopek zdravljenja raka z uporabo le-tega

Country Status (19)

Country Link
US (1) US6890917B2 (ja)
EP (1) EP1373215B1 (ja)
JP (1) JP4213472B2 (ja)
KR (1) KR100831133B1 (ja)
CN (1) CN1262542C (ja)
AT (1) ATE334119T1 (ja)
AU (1) AU2002307020B2 (ja)
CA (1) CA2430692C (ja)
CY (1) CY1107484T1 (ja)
DE (1) DE60213386T2 (ja)
DK (1) DK1373215T3 (ja)
ES (1) ES2268068T3 (ja)
IL (2) IL156122A0 (ja)
MX (1) MXPA03007856A (ja)
NZ (1) NZ526133A (ja)
PT (1) PT1373215E (ja)
SI (1) SI21369A (ja)
WO (1) WO2002079167A1 (ja)
ZA (1) ZA200304178B (ja)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
US20060148776A1 (en) * 2003-03-13 2006-07-06 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US20050054625A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
US20050026893A1 (en) * 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
US7691838B2 (en) * 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
US20050054589A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
US20050020557A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
US20050020534A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
WO2005009345A2 (en) 2003-06-13 2005-02-03 Kosan Biosciences, Inc. 2-desmethyl ansamycin compounds
CA2545457A1 (en) 2003-11-12 2005-06-23 Kosan Biosciences, Inc. 11-o-methylgeldanamycin compounds
US6887993B1 (en) 2003-11-12 2005-05-03 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6875863B1 (en) 2003-11-12 2005-04-05 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6855705B1 (en) 2003-11-12 2005-02-15 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US20060019941A1 (en) * 2003-12-23 2006-01-26 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
AU2004309395C1 (en) 2003-12-23 2012-10-04 Infinity Discovery, Inc. Analogs of benzoquinone-containing ansamycins for the treatment of cancer
US20050256097A1 (en) * 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
US7259156B2 (en) 2004-05-20 2007-08-21 Kosan Biosciences Incorporated Geldanamycin compounds and method of use
US20060067953A1 (en) * 2004-09-29 2006-03-30 Conforma Therapeutics Corporation Oral pharmaceutical formulations and methods for producing and using same
US7608611B2 (en) * 2005-03-11 2009-10-27 The Regents Of The University Of Colorado Hsp90 inhibitors, methods of making and uses therefor
AU2006242446A1 (en) * 2005-04-29 2006-11-09 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either in combination with a proteasome inhibitor
EP1906950A4 (en) * 2005-06-21 2008-09-24 Infinity Discovery Inc ANSAMYCIN FORMULATIONS AND METHODS OF USE
WO2007059116A2 (en) * 2005-11-14 2007-05-24 Abraxis Bioscience, Inc. Geldanamycin derivatives and pharmaceutical compositions thereof
US20090042847A1 (en) * 2005-11-23 2009-02-12 Kosan Biosciences Incorporated 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
US7648976B2 (en) * 2005-11-23 2010-01-19 Bristol-Myers Squibb Company 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
US20070167422A1 (en) * 2006-01-18 2007-07-19 Yu Kwok S Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
US20070207992A1 (en) * 2006-02-21 2007-09-06 Board Of Trustees Of Michigan State University Geldanamycin derivatives and method of use thereof
CN100519536C (zh) * 2006-03-21 2009-07-29 中国医学科学院医药生物技术研究所 一组连有核苷碱基的格尔德霉素衍生物
WO2007130403A2 (en) * 2006-05-02 2007-11-15 University Of Pittsburgh-Of The Commonwealth System Of Higher Education REGULATION OF ApoB BY Hspl 10 PROTEINS AND RELATED COMPOSITIONS AND METHODS
KR100796637B1 (ko) * 2006-09-29 2008-01-22 한국생명공학연구원 젤다나마이신 유도체, 이의 약학적으로 허용가능한 염,이의 제조방법 및 이를 유효성분으로 함유하는 암 예방 및치료제
CN100500668C (zh) * 2006-12-19 2009-06-17 中国人民解放军军事医学科学院毒物药物研究所 格尔德霉素衍生物及其制备方法和制备药物的用途
EP2121957A4 (en) * 2007-01-26 2010-11-10 Kosan Biosciences Inc MACROLACTAMES OBTAINED BY MODIFIED BIOSYNTHESIS
WO2008118601A2 (en) * 2007-02-27 2008-10-02 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Radiolabeled affibody molecules
US20100111943A1 (en) * 2007-03-22 2010-05-06 Medical College Of Georgia Research Institute, Inc Compositions and methods for inhibiting cancer metastasis
CA2684211A1 (en) * 2007-04-12 2008-10-23 Infinity Discovery, Inc. Hydroquinone ansamycin formulations
WO2009026548A1 (en) 2007-08-23 2009-02-26 The Regents Of The University Of Colorado Hsp90 inhibitors with modified toxicity
JP2011501731A (ja) 2007-09-10 2011-01-13 ユニバーシティ オブ マサチューセッツ ミトコンドリア標的化抗腫瘍剤
US20090186039A1 (en) * 2008-01-18 2009-07-23 Jang Sung-Key Novel use of grp 94 in virus infection
US20090258869A1 (en) * 2008-02-08 2009-10-15 The Regents Of The University Of California Methods and compounds for treatment or prevention of substance-related disorders
JP5583680B2 (ja) 2008-10-15 2014-09-03 インフィニティー ファーマスーティカルズ インコーポレイテッド アンサマイシンヒドロキノン組成物
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
EP2471918A4 (en) 2009-09-29 2013-06-05 Takeda Pharmaceutical SCREENING PROCESS
CN102030764B (zh) * 2010-11-12 2012-07-04 中国医学科学院医药生物技术研究所 4，5双氢噻嗪酮格尔德霉素及其制备方法
WO2012082765A2 (en) 2010-12-16 2012-06-21 The United State Of America. As Represented By The Secretary Department Of Health And Human Services Methods for decreasing body weight and treating diabetes
CN102603635B (zh) * 2011-01-21 2016-08-03 杭州华东医药集团生物工程研究所有限公司 格尔德霉素衍生物及其制备方法和用途
US8921533B2 (en) 2011-07-25 2014-12-30 Chromatin Technologies Glycosylated valproic acid analogs and uses thereof
US9603829B2 (en) 2011-11-14 2017-03-28 The Regents Of The University Of Colorado, A Body Corporate HSP90 inhibitors with modified toxicity
CN102552150B (zh) * 2012-03-02 2013-10-30 首都医科大学 一种格尔德霉素脂质体的制备及应用
WO2018160772A1 (en) 2017-02-28 2018-09-07 The United State Of America, As Represented By The Secretary, Department Of Health & Human Services Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55111470A (en) 1979-02-19 1980-08-28 Kaken Pharmaceut Co Ltd Geldanamycin derivative, its preparation, antitumor drug comprising it as active ingredient
JPS55111469A (en) 1979-02-19 1980-08-28 Kaken Pharmaceut Co Ltd Novel geldanamycin derivative, its preparation, and antitumor drug comprising it as active ingredient
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
JPS55111419A (en) 1979-02-20 1980-08-28 Kaken Pharmaceut Co Ltd Antitumorigenic agent
CA2166320A1 (en) * 1993-06-29 1995-01-12 Randall James Gallaschun Ansamycin derivatives as antioncogene and anticancer agents
DE69427588T2 (de) * 1993-09-14 2002-04-25 Merck & Co., Inc. HUMANE PROTEIN-TYROSINPHOSPHATASE DECODIERENDE cDNA
US5932566A (en) * 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
CA2218523A1 (en) * 1995-05-02 1996-11-07 William J. Welch Inducement of thermotolerance with benzoquinonoid ansamycins
US5958892A (en) * 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
US5948814A (en) * 1997-02-20 1999-09-07 The Curators Of The University Of Missouri Genistein for the treatment of cystic fibrosis
US5952175A (en) * 1997-10-09 1999-09-14 Incyte Pharmaceuticals, Inc. DNA encoding a human progesterone receptor complex p23-like protein
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration

Also Published As

Publication number Publication date
DK1373215T3 (da) 2006-11-13
CA2430692A1 (en) 2002-10-10
CA2430692C (en) 2011-05-31
CY1107484T1 (el) 2013-03-13
WO2002079167A1 (en) 2002-10-10
MXPA03007856A (es) 2003-12-04
JP4213472B2 (ja) 2009-01-21
DE60213386T2 (de) 2006-11-23
ES2268068T3 (es) 2007-03-16
CN1262542C (zh) 2006-07-05
EP1373215A1 (en) 2004-01-02
IL156122A0 (en) 2003-12-23
KR100831133B1 (ko) 2008-05-20
CN1484639A (zh) 2004-03-24
IL156122A (en) 2010-11-30
EP1373215B1 (en) 2006-07-26
NZ526133A (en) 2005-08-26
PT1373215E (pt) 2006-12-29
JP2004519514A (ja) 2004-07-02
US6890917B2 (en) 2005-05-10
US20040053909A1 (en) 2004-03-18
ATE334119T1 (de) 2006-08-15
DE60213386D1 (de) 2006-09-07
AU2002307020B2 (en) 2007-06-28
KR20040023581A (ko) 2004-03-18
ZA200304178B (en) 2004-02-17

Similar Documents

Publication Publication Date Title
SI21369A (sl) Geldanamicinski derivat in postopek zdravljenja raka z uporabo le-tega
AU2002307020A1 (en) Geldanamycin derivative and method of treating cancer using same
JP5838157B2 (ja) Ｈｄａｃ阻害剤およびそれを用いる治療法
CN103687853B (zh) 新型双氨基喹啉化合物及其制备的药物组合物和它们的用途
KR20210018291A (ko) 항암 핵 호르몬 수용체-표적화 화합물
JP2018521095A (ja) 変異イソクエン酸デヒドロゲナーゼｉｄｈ１ ｒ１３２ｈの阻害剤
CA2295640A1 (en) Aroylpiperazines for modulating sexual activity
WO2018204370A1 (en) Cx3cr1 small molecule antagonists, and methods using same
WO2002036574A1 (en) Geldanamycin derivatives useful for the treatment of cancer
WO2011025805A1 (en) Alkyl indole-3-carbinol-derived antitumor agents
JPH11506763A (ja) ニューモシスティス・カリニ肺炎の抑制方法及びそのために有効な化合物
WO2022006412A2 (en) Conjugates of ampk inhibitors and protac degraders and related uses
TWI721697B (zh) 用於治療骨關節炎的化合物
GB2592555A (en) Cancer
EP0831811B1 (en) Carbazoles for treating microbial infections
CN113710660B (zh) Dot1l降解剂及其用途
US20150044293A1 (en) Radioprotector compounds
EA039778B1 (ru) Фармацевтическая композиция, содержащая производные индола, способ ее получения и применение
EP3878444B1 (en) (n-(2-((2-benzylphenyl)amino)-2-oxoethyl)-l-naphthamide) as anticancer therapeutic agent
JP2002535276A (ja) ４−デメチルペンクロメジンのアシル誘導体、その使用及び調製
KR20130130802A (ko) 보르트만닌 유사체의 결정질 형태의 조성물 및 이의 사용 방법
KR100983318B1 (ko) 메조-비스(오쏘-하이드록시페닐)비스(오쏘-하이드록시)살렌의 항암제로서의 용도
WO2021046178A1 (en) Compounds and methods for treating cancer
WO2021046220A1 (en) Compounds and methods for treating cancer
WO2023122612A2 (en) Compounds for treatment of cancer

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20120405